EGFR-IN-135

• UNSPSC Description:

  EGFR-IN-135 (compound 3d) is a EGFR inhibitor with the IC50 of 0.086 µM. EGFR-IN-135 inhibitor cell growth and arrests the cell cycle at the S phase of reast cancer cell lines[1].

• Target Antigen:

  EGFR

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/egfr-in-135.html

• Smiles:

  CC1=C(C2=NN=C(SCC(C)C)O2)N3C(SC=C3)=N1

• Molecular Weight:

  294.40

• References & Citations:

  [1]Mohammed ER, et al. Synthesis of S-alkylated oxadiazole bearing imidazo[2,1-b]thiazole derivatives targeting breast cancer: In vitro cytotoxic evaluation and in vivo radioactive tracing studies. Bioorg Chem. Published online November 2, 2024.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported